This is an aggregated industry headline. Read the full story at FierceBiotech →
BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fields
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperwork with the Securities and Exchange Commission to publicly offer stock for the first time.
By FierceBiotech
· Jul 18, 2026
· via FierceBiotech
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
The FDA has converted its accelerated approval for Novartis' Fabhalta into a full blessing to treat patients w…
The WeekBriefing
The European Commission cleared Novo Nordisk’s oral Wegovy, giving the company a head start over Eli Lilly’s s…
The WeekSTAT News ↗
"The real opportunity is to move beyond policies and narratives that pit specialties against one another," pre…